StockData
ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc. (SPRY) stock

SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$3.69+0.04 (+1.10%)

Close on Nov 18, 2026Market cap $366.96MP/E –Yield –

ARS Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2023 it was $30.00K.

Annual gross profit

PeriodPeriod endValueChange
FY2023Dec 31, 2023$30.00K–

More ARS Pharmaceuticals figures

See a number that looks wrong?